Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D1.172 - Parallel Trajectories of Lung Function and Allergic Sensitization in Childhood Asthma: A 7-Year Prospective Study
D1.180 - Hidden fragility behind optimal ACT score: identifying silent-risk phenotypes through clinical-biological dissociation
D1.182 - Relationship between eHealth Literacy and Medication Adherence in Patients with Asthma: The Mediating Role of Self-Efficacy
D1.171 - Real-World Exacerbation Outcomes After AIR Therapy Rescue Implementation: Toward a SABA-Free Era
D1.173 - Sputum Tryptase Identifies Airway Mast Cell Activation Across Asthma Phenotypes
D1.174 - Framing ADAM17 alterations across bronchial, sputum and nasal sites in asthma and controls
D1.175 - Clinical Phenotypes of Difficult-to-treat and Mild Asthma Defined by Cluster Analysis
D1.176 - Prognostic Evaluation of the Allergic March in Patients with Atopic Dermatitis
D1.177 - Turkish Validity and Reliability of the Medication Adherence Report Scale for Asthma (MARS-A) in Adolescents with Asthma
D1.178 - Real-World Comparison of Inhaled Corticosteroid Monotherapy versus Fixed-Dose Inhaled Corticosteroid–Long-Acting Beta-2 Agonist Combinations in Children Aged 6–11 Years with Persistent Asthma
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)
D1.441 - A Bispecific Antibody Targeting IL13 and IL31 for the Treatment of Inflammatory Skin Diseases
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download